CVS to Remove AbbVie’s Humira from Reimbursement Lists, Cover Biosimilars

CVS Caremark, the pharmacy benefit management subsidiary of CVS Health, on Wednesday announced that it would remove AbbVie’s arthritis therapy Humira (adalimumab) from its major national commercial template formularies, and that it would instead cover the medication’s biosimilars.